SERM Market Shows Promising Growth Trajectory During the Study Period (2020-2034) Owing to the Rising Demand in Oncology and Women's Health
LAS VEGAS, July 17, 2025 /PRNewswire/ — DelveInsight's SERM Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as breast cancer, postmenopausal osteoporosis, dyspareunia and vaginal dryness, and others. The selected indications are based on approved therapies and ongoing pipeline activity. The report also provides insights into the emerging SERM, market share of individual therapies, and current and forecasted market size from 2020 to 2034, segmented into 7MM.
Key Takeaways from the SERM Market Report
As per DelveInsight's analysis, the total market size of SERM in the 7MM is expected to surge significantly by 2034.
The report provides the total potential number of patients in the indications, such as breast cancer, postmenopausal osteoporosis, dyspareunia and vaginal dryness, and others.
Leading SERM companies, such as Atossa Therapeutics, Sermonix Pharmaceuticals, and others, are developing novel SERMs that can be available in the SERM market in the coming years.
Some of the key SERMs in the pipeline include (Z)-Endoxifen, Lasofoxifene, and others.
In April 2025, Atossa Therapeutics announced that the US Patent and Trademark Office (USPTO) had granted a new patent (US Patent No. 12,275,684) directed to enteric oral formulations comprising (Z)-Endoxifen as well as methods of treating subjects with those oral formulations.
In April 2025, Sermonix Pharmaceuticals and Quantum Leap Healthcare Collaborative broadly announced that in the Phase II clinical trial evaluating lasofoxifene as a neoadjuvant endocrine therapy in molecularly selected HR+/HER2-, locally advanced breast cancer, the investigational drug was well tolerated and demonstrated promising early activity in suppressing the Ki67 protein in both premenopausal and postmenopausal patients.
In January 2025, Sermonix Pharmaceuticals announced the publication of an article entitled 'Effects of Lasofoxifene Versus Fulvestrant on Vaginal and Vulvar Symptoms in Patients with ESR1-Mutated, ER+/HER2-, Metastatic Breast Cancer from the ELAINE-1 Study', in the peer-reviewed journal Clinical Breast Cancer.
Discover which indication is expected to grab the major SERM market share @ SERM Market Report
SERM Market Dynamics
The SERM market is witnessing dynamic growth, driven by an increasing prevalence of hormone-related disorders such as breast cancer, osteoporosis, and infertility. SERMs function by selectively stimulating or inhibiting estrogen receptors in different tissues, offering therapeutic benefits without the widespread side effects of hormone replacement therapy. With rising global awareness of women's health issues and increasing access to healthcare in emerging markets, the demand for SERMs is projected to grow steadily. Additionally, advancements in personalized medicine are supporting the use of SERMs in targeted therapies, particularly in oncology and postmenopausal care.
A key driver of the SERM market is the high incidence of hormone receptor-positive breast cancer. As oncology treatment paradigms shift toward more targeted, less toxic therapies, SERMs continue to play a critical role in both adjuvant and preventive settings. Moreover, their utility in conditions such as osteoporosis supports their broader adoption in geriatric medicine.
However, market growth is tempered by several factors, including the emergence of alternative therapies such as aromatase inhibitors and biologics, which offer improved efficacy in certain indications. Concerns around side effects, such as thromboembolic events and endometrial cancer risk with long-term SERM use, have also led to cautious prescribing practices. Additionally, generic competition has eroded profit margins for several first-generation SERMs, prompting pharmaceutical companies to invest in next-generation compounds with better safety and efficacy profiles.
Innovation remains a key aspect of the market dynamics, with ongoing research exploring newer SERMs that can provide tissue-specific actions with reduced adverse effects. These next-generation SERMs aim to expand therapeutic applications beyond traditional indications, including cardiovascular health and cognitive disorders in postmenopausal women. Strategic collaborations, licensing deals, and regulatory approvals are shaping the competitive landscape, with companies focusing on differentiated product offerings and combination therapies.
In summary, the SERM market is marked by a strong clinical foundation, expanding therapeutic applications, and evolving competition. As aging populations and hormone-related conditions continue to rise globally, the demand for SERMs is expected to remain robust. Nevertheless, future growth will depend on continued innovation, improved safety profiles, and integration into broader personalized treatment strategies.
SERM Treatment Market
SERMs are utilized in the treatment of various estrogen-related conditions. These include managing ovulatory dysfunction in infertility, preventing and treating postmenopausal osteoporosis, treating and lowering the risk of breast cancer, and addressing dyspareunia caused by menopause. SERMs are also combined with conjugated estrogens to manage estrogen deficiency and vasomotor symptoms linked to menopause. Their usage is tailored based on their tissue-specific activity.
Tamoxifen is a primary hormonal therapy for estrogen receptor (ER)-positive metastatic breast cancer and is also prescribed for reducing breast cancer risk in high-risk women. It serves as an adjuvant therapy in ductal carcinoma in situ with or without axillary node involvement. Additionally, tamoxifen helps improve bone density and lipid profiles in postmenopausal women.
Toremifene, a derivative of tamoxifen with chlorine substitution, was developed to reduce liver-related side effects such as DNA adduct formation and potential hepatic tumors. It is used as endocrine therapy in ER/PR-positive stage IV or recurrent metastatic breast cancer and has shown comparable efficacy to tamoxifen in both adjuvant and metastatic settings.
OSPHENA (ospemifene), an estrogen receptor agonist/antagonist, is approved for the treatment of moderate to severe dyspareunia and vaginal dryness resulting from vulvovaginal atrophy due to menopause. Initially approved by the US FDA in 2013 and marketed by Shionogi, it later gained EU approval in 2015. In 2017, Duchesnay obtained exclusive marketing rights for OSPHENA in the US and Canada.
DUAVEE (marketed as DUAVIVE in the EU) combines conjugated estrogens with a SERM and is indicated for treating moderate to severe vasomotor symptoms of menopause and for preventing postmenopausal osteoporosis. It was approved for use in the US in October 2013 and in the EU in December 2014.
Learn more about the SERM @ SERM Analysis
Key Emerging SERM and Companies
Several key players, including Atossa Therapeutics ((Z)-Endoxifen), Sermonix Pharmaceuticals (Lasofoxifene), and others are involved in developing drugs for SERMs for various indications such as breast cancer, dyspareunia and vaginal dryness, and others. Overall, this is an exciting new class of agents with great potential for development.
(Z)-Endoxifen, developed by Atossa Therapeutics, is a nonsteroidal selective estrogen receptor modulator (SERM) from the triphenylethylene class, currently in Phase II development for estrogen receptor-positive (ER+) breast cancer. This agent shows promise across multiple stages of breast cancer management: lowering breast tissue density to reduce cancer risk, decreasing cancer cell activity before surgery, and helping prevent recurrence or new tumors following initial treatment. Atossa is advancing (Z)-Endoxifen with a focus on treating metastatic breast cancer.
In April 2025, Atossa announced that the U.S. Patent and Trademark Office granted a new patent (US Patent No. 12,275,684) covering enteric oral formulations of (Z)-Endoxifen and their use in treatment methods. Earlier, in December 2024, the company presented three posters at the San Antonio Breast Cancer Symposium (SABCS), showcasing pharmacokinetic and tolerability findings from the ongoing Phase II EVANGELINE trial.
Lasofoxifene is a novel investigational endocrine therapy being studied for its effectiveness as an ESR1 antagonist, particularly in tumors with ESR1 mutations. It has demonstrated notable anti-tumor activity both as a standalone treatment and when used with a CDK4/6 inhibitor in Phase II trials. Lasofoxifene is distinguished by its selective activity in different tissues, with previously observed benefits for vaginal and bone health.
In April 2025, Sermonix Pharmaceuticals and Quantum Leap Healthcare Collaborative reported encouraging Phase II data from a neoadjuvant trial of lasofoxifene in patients with HR+/HER2- locally advanced breast cancer, showing good tolerability and early suppression of the proliferation marker Ki67 in both premenopausal and postmenopausal women. Earlier, in January 2025, Sermonix published findings in Clinical Breast Cancer from the ELAINE-1 study, comparing lasofoxifene and fulvestrant, highlighting lasofoxifene's positive effects on vaginal and vulvar symptoms in ESR1-mutated, ER+/HER2- metastatic breast cancer patients.
The anticipated launch of these emerging therapies are poised to transform the SERM market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the SERM market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.
To know more about SERM clinical trials, visit @ SERM Treatment
SERM Overview
Selective estrogen receptor modulators (SERMs), also referred to as estrogen receptor agonists/antagonists (ERAAs), are a group of compounds that interact with estrogen receptors (ERs). Unlike full agonists or pure antagonists, SERMs exhibit tissue-specific actions, meaning they can either stimulate or block estrogenic effects depending on the target tissue. This selective behavior is due to their ability to bind to the two estrogen receptor subtypes, ERα and ERβ, in ways that influence their activity uniquely across different tissues. The resulting effects are determined by how SERMs modify signaling pathways in a tissue-dependent manner, rather than by directly altering DNA. In the context of bone health, SERMs help regulate bone metabolism by decreasing osteoclast activity via a mechanism involving transforming growth factor-β3, leading to reduced bone resorption and thereby supporting the prevention and treatment of osteoporosis.
SERM Epidemiology Segmentation
The SERM market report proffers epidemiological analysis for the study period 2020–2034 in the 7MM, segmented into:
Total Cases of Selected Indication for SERM
Total Eligible Patients of the Selected Indications
Total Treated Cases in Selected Indications for SERMs
SERM Report Metrics
Details
Study Period
2020–2034
SERM Report Coverage
7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]
Key Indications Covered in the Report
Breast cancer, Postmenopausal osteoporosis, Dyspareunia and vaginal dryness, and others
Key SERM Companies
Atossa Therapeutics, Sermonix Pharmaceuticals, Duchesnay, Pfizer, Eli Lilly, and others
Key SERM
(Z)-Endoxifen, Lasofoxifene, OSPHENA, DUAVEE, EVISTA (raloxifene hydrochloride), FABLYN, and others
Scope of the SERM Market Report
SERM Therapeutic Assessment: SERM current marketed and emerging therapies
SERM Market Dynamics: Conjoint Analysis of Emerging SERM Drugs
Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
Unmet Needs, KOL's views, Analyst's views, SERM Market Access and Reimbursement
Discover more about SERMs in development @ SERM Clinical Trials
Table of Contents
1
Key Insights
2
Report Introduction
3
Executive Summary of SERM
4
Key Events
5
Market Forecast Methodology
6
SERM Market Overview at a Glance in the 7MM
6.1
Market Share (%) Distribution by Indication in 2024
6.2
Market Share (%) Distribution by Indication in 2034
7
SERM: Background and Overview
8
Treatment and Management
9
Target Patient Pool
9.1
Key Findings
9.2
Assumptions and Rationale: 7MM
9.3
Epidemiology Scenario in the 7MM
9.3.1
Total Cases of Selected Indication for SERM in the 7MM
9.3.2
Total Eligible Patient Pool for SERM in Selected Indication in the 7MM
9.3.3
Total Treatable Cases in Selected Indication for SERM in the 7MM
10
Marketed Therapies
10.1
Key Competitors
10.2
OSPHENA (ospemifene): Duchesnay
10.2.1
Product Description
10.2.2
Regulatory milestones
10.2.3
Other developmental activities
10.2.4
Clinical development
10.2.5
Safety and efficacy
10.3
DUAVEE (conjugated estrogens/bazedoxifene): Pfizer
10.3.1
Product Description
10.3.2
Regulatory milestones
10.3.3
Other developmental activities
10.3.4
Clinical development
10.3.5
Safety and efficacy
List to be continued in the report…
11
Emerging Therapies
11.1
Key Competitors
11.2
(Z)-Endoxifen: Atossa Therapeutics
11.2.1
Product Description
11.2.2
Other developmental activities
11.2.3
Clinical development
11.2.4
Safety and efficacy
11.3
Lasofoxifene: Sermonix Pharmaceuticals
11.3.1
Product Description
11.3.2
Other developmental activities
11.3.3
Clinical development
11.3.4
Safety and efficacy
List to be continued in the report…
12
SERM: Seven Major Market Analysis
12.1
Key Findings
12.2
Market Outlook
12.3
Conjoint Analysis
12.4
Key Market Forecast Assumptions
12.4.1
Cost Assumptions and Rebates
12.4.2
Pricing Trends
12.4.3
Analogue Assessment
12.4.4
Launch Year and Therapy Uptakes
12.5
Total Market Size of SERM in the 7MM
12.6
The United States
12.7
EU4 and the UK
12.8
Japan
13
SWOT Analysis of SERM
14
KOL Views of SERM
15
Unmet Needs of SERM
16
Market Access and Reimbursement
17
Bibliography
18
Report Methodology
Related Reports
Metastatic HR+/HER2− Breast Cancer Market
Metastatic HR+/HER2− Breast Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key metastatic HR+/HER2− breast cancer companies, including Merck, Arvinas, Olema Pharmaceuticals, Celcuity, Roche, AstraZeneca, Daiichi Sankyo, Eli Lilly, Sermonix Pharmaceuticals, Genentech, Veru Pharma, DualityBio, BioNtech, Evgen Pharma, Carrick Therapeutics, EQRx, G1 Therapeutics, Immutep, among others.
Metastatic HER2-positive Breast Cancer Market
Metastatic HER2-positive Breast Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key metastatic HER2-positive breast cancer companies, including Byondis, Tanvex Biopharma, Prestige BioPharma, EirGenix, AMbrx, CSPC ZhongQi Pharmaceutical Technology Co., Ltd., Roche, Jiangsu Alphamab Oncology Co., Ltd., Jiangsu HengRui Medicine Co., Ltd., RemeGen, Shanghai Henlius Biotech, Merus N.V., Hangzhou DAC Biotech, Lepu Biopharma, Zymeworks, Klus Pharma Inc., Bolt Biotherapeutics, GeneQuantum Healthcare, ALX Oncology, Precirix, BriaCell Therapeutics Corporation, Bliss Biopharmaceutical, BioInvent International, Incyte Corporation, Triumvira Immunologics, Inc., Horizon Therapeutics, among others.
Breast Cancer Market
Breast Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key breast cancer companies, including Veru, Sanofi, Roche, AstraZeneca, Eli Lilly, EQRx, Gilead, Sermonix Pharmaceuticals, Evgen Pharma, Tyme, Genentech, Daiichi Sankyo, among others.
Postmenopausal Osteoporosis Market
Postmenopausal Osteoporosis Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key postmenopausal osteoporosis companies, including Suzhou Suncadia Biopharmaceuticals, Shanghai Henlius Biotech, Inc., Mabpharm Limited, Alvotech, Samsung Bioepis Co., Ltd., Biocon Biologics, Entera Bio Ltd., Genor Biopharma Co., Ltd., Addpharma, among others.
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.
Contact UsShruti Thakurinfo@delveinsight.com +14699457679
Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg
View original content:https://www.prnewswire.co.uk/news-releases/serm-market-shows-promising-growth-trajectory-during-the-study-period-20202034-owing-to-the-rising-demand-in-oncology-and-womens-health–delveinsight-302507684.html
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Sun
18 minutes ago
- The Sun
China eyes new measures to boost economy
BEIJING: China has a 'plentiful' toolbox to avoid an economic slump in the second half of the year, its commerce minister said yesterday as he admitted it faced a 'very severe and complex situation'. Growth hit 5.2% in the second quarter, official data showed Tuesday, but analysts have warned that more must be done to boost sluggish domestic consumption as exports face the knock-on effects of global trade turmoil. Retail sales rose far less than expected last month and were much weaker than May, suggesting efforts to kickstart consumption have fallen flat. 'We are still facing a very severe and complex situation. Global changes are unstable and uncertain. Some of our policies will offer some new responses according to the times and circumstances,' Wang Wentao told journalists at a news briefing. 'Our toolbox is plentiful, and we will be fully prepared.' Asked specifically about China's reliance on exports, Wang suggested the government was preparing policies to 'further stimulate the momentum of our consumption development'. 'China's economy is improving, and the long-term fundamentals have not changed, the consumption market's characteristics of great potential, strong resilience and vitality have not changed,' he said. Wang also namechecked Beijing-based toymaker Pop Mart, whose Labubu monster dolls have become a must-have item internationally, adorning the handbags of celebrities such as Rihanna and Dua Lipa. 'We are also promoting new forms of consumption... for example Pop Mart, these kinds of new trends, new fashions and styles... the Labubu phenomenon has swept the world,' he said. Beijing is battling to shift towards a growth model propelled more by domestic demand than the traditional key drivers of infrastructure investment, manufacturing and exports. That desired transformation has become more urgent since Donald Trump came to office. The US president has imposed tariffs on China and other key trade partners, disrupting trade norms and threatening Beijing's exports at a crucial time for its economy. The two superpowers have sought to de-escalate their row after reaching a framework for a deal at talks in London last month, but observers warn of lingering uncertainty. Wang said yesterday that despite 'storms and rain', Washington remained an important trading partner. Even though China-US trade has declined proportionally for each country, overall bilateral trade has remained stable, Wang said. In a sign of progress, US tech giant Nvidia said this week that it would resume sales of its H20 artificial intelligence chips to China after Washington pledged to remove licensing restrictions that had halted exports. China's commerce ministry acknowledged the US decision in a statement yesterday afternoon, even as it called for Washington to 'abandon its zero-sum mentality'. Nvidia CEO Jensen Huang has met with Chinese leaders this week in Beijing, telling journalists Wednesday that his firm was 'doing our best' to serve the country's vast semiconductor market. – AFP
Malaysian Reserve
18 minutes ago
- Malaysian Reserve
US to impose steep anti-dumping duty on battery material from China
WASHINGTON — The United States unveiled on Thursday preliminary anti-dumping duties of 93.5 percent on imports of a key battery component from China, after looking into a petition on the matter. Final determinations regarding duties on graphite are expected in early December, according to the US Commerce Department. Its investigation came after a petition by the American Active Anode Material Producers, an ad-hoc coalition including US graphite producers, late last year. Graphite is an important raw material used in making anodes of batteries, and China is a dominant player when it comes to its processing capacity of graphite. The duty could raise temperatures in the global electric vehicle supply chain, potentially adding to costs for automakers who rely on the material for production. The products covered under the investigation includes active anode material, whether or not they are contained in finished batteries. China and the United States are now engaged in negotiations about their broader economic relationship after reaching a framework for a deal last month, stepping back from the brink of a spiraling trade war. Asked about the new graphite duties, Beijing's foreign ministry said Friday that 'the essence of China-US economic and trade cooperation is mutual benefit and win-win results'. 'It is hoped the US side will conscientiously abide by the rules of the market economy and maintain the healthy and stable development of China-US economic and trade relations,' spokesman Lin Jian said. The US Commerce Department's notice came after Washington took aim at solar imports from Southeast Asia as well earlier this year. Since returning to the White House in January, President Donald Trump has also separately targeted sector-specific imports with tariffs, including 50 percent duties on imported steel and aluminum, alongside other levies on autos. — AFP
The Sun
18 minutes ago
- The Sun
Japan's SMEs ready to adapt to Trump tariffs
TOKYO: Small and medium-sized firms (SME) like Mitsuwa Electric that form the backbone of Japan's economy have weathered many storms over the decades, and company president Yuji Miyazaki is hopeful they will also withstand Donald Trump. As part of a campaign against friend and foe, the US president has threatened 25 % tariffs on imports of Japanese goods from Aug 1, having already imposed tough levies on its vehicles, steel and aluminium. However, Miyazaki told AFP that he was confident. 'We are providing very specialised products for specialised industries, where it is difficult to change suppliers or supplying countries just because of boosted tariffs,' he said on a tour of the 92-year-old firm. 'I'm not worried too much, because if American companies can't produce parts on their own, they have no choice but to import those parts regardless of tariffs,' the descendant of the firm's founder said. With 100 employees, Mitsuwa Electric is not a household name. But like millions of other SMEs that account for 99.7 % of Japan's companies, it is world-class in its specialist niche. It began making light bulb filaments and now produces coils, rods, needles, plates, pipes and wires for a range of goods including car lights, photocopiers and X-ray machines. In 2022, it won a Guinness World Record for the smallest commercially available metal coil, with a diameter around half that of a human hair. Mitsuwa's customers are across Asia, Europe and North America and include Japanese engineering giant Toshiba and Toyota-affiliated parts maker Koito Manufacturing. Miyazaki said the impact of US tariffs on the company's business is limited so far, with one auto sector customer asking it to lower prices. 'All we can do is to adapt to any changes in the business environment,' Miyazaki said. Prime Minister Shigeru Ishiba has sent his tariffs envoy Ryosei Akazawa to Washington seven times since April to try to win relief from the tariffs. US Treasury Secretary Scott Bessent was due to meet Ishiba and Akazawa yesterday in Tokyo. But the prime minister's apparently maximalist strategy of insisting all tariffs are cut to zero have been criticised in some parts, especially as Aug 1 approaches. US-bound exports of Japanese vehicles – a sector tied to 8% of Japanese jobs – tumbled around 25% in May and June. The lack of a deal isn't helping Ishiba's popularity ahead of upper house elections on Sunday that may end Ishiba's premiership after less than a year. What bothers Japanese firms is Trump's unpredictability and the complexity of the tariffs, according to government-backed SME support organisation Jetro. Since February, the group has received more than 2,000 enquiries from members about US tariffs, with a flood of requests since June asking for 'the latest information' as the deadline approaches. Mitsuwa Electric boss Miyazaki admits worrying about Trump's threat of pharmaceuticals tariffs of 200%, or if medical equipment is targeted. He said that its wide product range and diverse customer base have protected it so far. This is also vital for other firms to survive, said Zenkai Inoue, an SME expert and professor at the Kyushu Institute of Information Sciences. 'I'm proposing a 'tricycle strategy', which means you have to have (at least) three customers in different regions,' he told AFP.
